http://bmj.com/cgi/content/full/325/7360/356
| Home | Help | Search/Archive | Feedback | Table of Contents |
|
||||||||
 Collections under
which this article appears: Other
Oncology Ischaemic
heart disease |
Aspirin, already known to reduce the risk of colon cancer, may also prevent cancer of the pancreas.
In a seven year study of more than 28000 postmenopausal women aged 55 to 69 who were participants in the Iowa women's health study, the risk of pancreatic cancer was 43% lower in women who took aspirin or products containing aspirin than in women who did not (relative risk 0.57 (95% confidence interval 0.36 to 0.90)). The more often that women took aspirin, the lower their risk of the cancer (Journal of the National Cancer Institute 2002;94:1168-71)[Abstract/Full Text].
A decreased incidence of pancreatic cancer with use of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown by other studies, all of which were studies of patients taking NSAIDs for other indications, such as rheumatoid arthritis. This is the first study to directly examine the relation between aspirin use and pancreatic cancer.
The study showed that the protective effects of aspirin increased with
frequency of use. Compared with women who never took aspirin, women
who took aspirin 2-5 times a week had a 53% lower risk and women who
took it 
6 times a week had a 60%
lower risk.
The study's lead author, Dr Kristin Anderson of the University of Minnesota in Minneapolis, said she and her colleagues "tried to make the effects of aspirin go away" by taking into account characteristics of the women that could have influenced the results, such as age, the presence of diabetes, and whether they smoked or took multivitamins. "Nothing made the aspirin effect go away," Dr Anderson said.
While the mechanism by which aspirin could reduce the incidence of pancreatic
cancer is not clear, it is thought to involve inhibition of
expression of cyclo-oxygenase 2
but
it probably involves other mechanisms as well, say the researchers.
In the study, other NSAIDs, such as ibuprofen, did not decrease the
incidence of pancreatic cancer, perhaps reflecting differences in
their mechanism of action, said Dr Anderson.
She cautioned, however, that the researchers did not have enough evidence to rule out that other NSAIDs may reduce the risk of pancreatic cancer. She said that the women in the study were asked in 1992 about their use of NSAIDs, when the drugs were not as widely used and some newer types had not yet been introduced.
The researchers did not collect data on the dose of aspirin the participants
took or on the length of time that they were taking aspirin before
enrolling in the study. They looked only at current use, which
precludes a comparison of short term and long term use. Also, the
homogeneity of the study populationpostmenopausal
women, 98% of whom were whitemakes
it difficult to generalise the results.
|
||||||||
|
Collections under
which this article appears:Other
Oncology Ischaemic
heart disease |
| Home | Help | Search/Archive | Feedback | Table of Contents |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.